新辅助药Nivolumab加Ipilimumab与化学疗法在切除的肺癌
Mark M Awad1, Patrick M Forde2, Nicolas Girard3
1Dana-Farber Cancer Institute, Boston, MA.
概括
新辅助药尼沃卢马布加上伊皮利穆马布在可切除的非小细胞肺癌 (NSCLC) 中显示出长期生存益处. 与化疗相比,这种免疫疗法组合显示出较好的无事件生存率和整体生存率,具有更好的安全性.
科学领域:
- 医学瘤学 医学瘤学
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 新辅助免疫检查点封锁是治疗非小细胞肺癌 (NSCLC) 的有希望的策略.
- 在可切除的NSCLC中,对于新辅助药尼沃卢马布加上伊皮利穆马布,存在有限的随机数据.
研究的目的:
- 报告来自CheckMate 816试验的探索性,同时随机分组的结果.
- 为了比较新辅助药尼沃卢马布加上伊皮利穆马布与可切除NSCLC的化疗.
主要方法:
- 患有IB-IIIA阶段切除性NSCLC的成年人接受了新辅助药尼沃卢马布加上伊皮利穆马布或化疗,然后进行手术.
- 分析包括无事件生存 (EFS),总生存 (OS),病理反应,手术结果和安全性.
主要成果:
- 在49.2个月的中位随访期内,尼沃卢马布加伊皮利穆马布的中位EFS为54.8个月,与化疗为20.9个月相比.
- 三年后的OS率为73%与61%相比,病理完整反应率为20.4%与4.6%,有利于尼沃卢马布加上伊皮利穆马布.
- 3-4级与治疗相关的不良事件在nivolumab加上ipilimumab (14%) 与化疗 (36%) 相比较低.
结论:
- 新辅助药尼沃马布加上伊皮利马布在可切除的NSCLC中显示出潜在的长期临床益处.
- 免疫疗法组合显示,与化疗相比,改善了生存结果和病理反应.
- 与新辅助药尼沃卢马布加上伊皮利穆马布治疗时,观察到较低的高度毒性.
相关概念视频
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


